ClinicalTrials.gg
RecruitingNCT07529171Updated Aug 4, 2026

HBV Reactivation in Immunocompromised Patients (REANT STUDY)

An observational study in HBV, sponsored by Yaşar Bayındır, MD. Recruiting at 16 sites in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Yaşar Bayındır, MD · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
490
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Background/Objective: Comorbidities represent a critical risk factor in the prognosis of patients receiving immunosuppressive therapy. For patients with anti-HBc IgG positivity requiring Hepatitis B virus (HBV) prophylaxis, the long-term physiological impact of oral antivirals remains a concern. This study aims to prospectively monitor bone, renal, and metabolic dysfunctions associated with oral antiviral use and other systemic risk factors over a long-term period.

Methods: The REANT Cohort is designed as a 4-year, multicenter prospective study. The cohort will consist of patients initiated on HBV prophylaxis due to immunosuppressive treatment. Participants will undergo regular longitudinal assessments to evaluate bone mineral density, renal filtration and tubular functions, and metabolic profiles. The interplay between antiviral therapy, baseline comorbidities, and long-term organ dysfunction will be analyzed.

Conclusion: The findings from the REANT Cohort are expected to provide robust evidence regarding the safety of long-term HBV prophylaxis and assist in the development of monitoring guidelines for immunosuppressed patients with latent HBV infection.

Read the detailed description

Patient Recruitment and Enrollment:

The patient enrollment phase for the study is scheduled to conclude on June 30, 2026. Each participating center is projected to enroll 35 patients, ensuring a balanced distribution of data across the multicenter framework. The study will be initiated simultaneously across all participating sites to maintain temporal consistency in data collection.

Electronic Case Report Form (e-CRF) and Coding:

Data will be managed through a centralized e-CRF system. To ensure systematic tracking and data integrity, the system will assign a unique center code to each participating institution.

Patient Identification and Confidentiality:

For each participant, a specific patient code will be automatically generated by the system. Following the standardized protocol of the study, the patient's Full Name must be entered into the system, formatted specifically with a hyphen between the first and last name (e.g., John-Doe). This structured nomenclature will ensure uniformity in the electronic database.

02

Conditions studied

  • HBV

Keywords

  • HBV reactivation
  • Immunosuppressive therapy
03

In context

Lead sponsor

Yaşar Bayındır, MD is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The REANT Cohort is designed as a nationwide, multicenter study conducted across 14 specialized centers in Türkiye. These centers have been strategically selected to reflect a broad geographical and demographic diversity, ensuring a robust representation of the patient population receiving HBV prophylaxis.

Participating Provinces:

The study will be carried out simultaneously in the following 13 provinces (with 14 participating clinical sites):

Ankara, Sivas, İstanbul, Kocaeli, İzmir, Antalya, Adana, Gaziantep, Şanlıurfa, Diyarbakır, Samsun, Rize, Düzce

Sample Size Projection:

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Positive for IgG
  • Must be candidate for therapy.

Exclusion criteria

Exclusion Criteria:

  • Voluntary Withdrawal
  • Failure to attend follow-up visits
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
490 participants (estimated)
Target follow-up
48 Months
Patient registry
Yes

Interventions

  • DrugAntiviral

    Patients who take all antivirals recommended in the guidelines will be evaluated in the same group.

    Also known as: Nucleoz(t)ide antivirals

06

What researchers measure

Primary outcomes

  1. Monitoring of renal function in patients receiving antivirals.

    To assess the composite changes in renal function (GFR decline, proteinuria, etc) from baseline to month 48.

    Time frame: Baseline to week 6, 12, 24, 48

  2. Monitoring of bone health in patients receiving antivirals.

    To assess the composite changes in bone health (Reduction in T-scores via DEXA) from baseline to month 48.

    Time frame: Baseline to week 6, 12, 24, 48

  3. Monitoring of metabolic status in patients receiving antivirals.

    To assess the composite changes in metabolic status (HOMA-IR elevation, lipid profile alterations, etc) from baseline to month 48.

    Time frame: Baseline to week 6, 12, 24, 48

Secondary outcomes

  1. Evaluation of liver status in the patients receiving HBV antivirals.

    To evaluate changes in liver status by FIB-4 over 48 months. FIB-4 Index (Fibrosis-4 Index) is a formula that combines four different parameters to estimate the degree of liver damage. These parameters are: Age, AST (Aspartate Aminotransferase) level, ALT (Alanine Aminotransferase) level, and platelet count.

    Time frame: Baseline to week 6, 12, 24, 48

  2. Evaluation of liver damage in the patients receiving HBV antivirals.

    To evaluate changes in liver status by APRI over 48 months. APRI (AST to Platelet Ratio Index) is a simpler calculation focusing on the relationship between liver enzyme elevation and the decrease in platelets often seen as liver disease progresses. Parameters Used: AST level, AST Upper Limit of Normal (ULN), Platelet Count.

    Time frame: Baseline to week 6, 12, 24, 48

  3. Evaluation of liver stiffness in the immunosuppressive patients receiving HBV antivirals for reactivation prophylaxis.

    To evaluate changes in liver status by Fibroscan (if available in the center) over 48 months. FibroScan (also known as Transient Elastography) is a non-invasive medical imaging technique used to measure the stiffness of the liver.

    Time frame: Baseline to week 6, 12, 24, 48

07

Study locations

16 of 16 sites recruiting
  • Cukurova University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Adana, Turkey (Türkiye)
    Recruiting
    • Yesim Tasova, MD, Prof. · Contactytasova@gmail.com · +905353088511
    • Yesim Tasova, MD, Prof. · Principal investigator
    • Suheyla Komur, MD, Prof. · Sub investigator
  • Ankara Gazi University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Ankara, Turkey (Türkiye)
    Recruiting
    • Yesim Yildiz, MD, Assoc. Prof. · Contactysmyldz6@gmail.com · +905556109871
    • Yesim Yildiz, MD, Assoc. Prof. · Principal investigator
  • Bilkent City Hospital Department of Infectious Diseases and Clinical Microbiology
    Ankara, Turkey (Türkiye)
    Recruiting
    • Aliye Bastug, MD, Prof. · Contactdr.aliye@yahoo.com · +905333814223
    • Aliye Bastug, MD, Prof. · Principal investigator
  • Akdeniz University, Faculty of Medicine, Department of Infectious Diseases and Clinical Mİcrobiology
    Antalya, Turkey (Türkiye)
    Recruiting
    • Dilara Inan, MD, Prof. · Contactdilarainan2004@yahoo.com · +905323706725
    • Dılara Inan, MD, Prof. · Principal investigator
  • Dicle University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Diyarbakır, Turkey (Türkiye)
    Recruiting
  • Diyarbakir, Memorial Hospital Department of Infectious Diseases and Clinical Microbiology
    Diyarbakır, Turkey (Türkiye)
    Recruiting
    • Yakup Demir, MD · Contactyakupdemir36@gmail.com · +905446540047
    • Yakup Demir, MD · Principal investigator
  • Bolu Düzce University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Düzce, Turkey (Türkiye)
    Recruiting
    • Nevin Ince, MD, Assoc. Prof. · Contactdrnevince@gmail.com · +905053505839
    • Nevin Ince, MD, Assoc. Prof. · Principal investigator
  • Gaziantep University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Gaziantep, Turkey (Türkiye)
    Recruiting
    • Ayse Ozlem Mete, MD, Assoc. Prof. · Contactayseozlem_ornek@hotmail.com · +905064883309
    • Ayse Ozlem Mete, MD, Assoc. Prof. · Principal investigator
    • Ilkay Karaoglan, MD, Prof. · Sub investigator
  • Istanbul Haydarpaşa Numune Training and Research Hospital
    Istanbul, Turkey (Türkiye)
    Recruiting
    • Seniha Senbayrak, MD, Prof. · Contactsenihasen@gmail.com · +905055618792
    • Seniha Senbayrak, MD, Prof. · Principal investigator
  • Istanbul Sancaktepe Martyr Prof. Dr. İlhan Varank Training and Research Hospital
    Istanbul, Turkey (Türkiye)
    Recruiting
  • Ege University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Izmir, Turkey (Türkiye)
    Recruiting
    • Husnu Pullukcu, MD, Prof. · Contacthusnup@yahoo.com · +905334231918
    • Husnu Pullukcu, MD, Prof. · Principal investigator
    • Tansu Yamazhan, MD, Prof. · Sub investigator
  • Kocaeli University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Kocaeli, Turkey (Türkiye)
    Recruiting
    • Sıla Akhan, MD, Prof. · Contactsilaakhan@gmail.com · +905322666535
    • Muge Toygar Deniz, MD, Assoc. Prof. · Sub investigator
    • Sila Akhan, MD, Assoc. Prof. · Principal investigator
  • Rize Recep Tayyip Erdogan University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Rize, Turkey (Türkiye)
    Recruiting
    • Ilknur Esen Yildiz, MD, Assoc. Prof. · Contactiesenyildiz61@gmail.com · +905057954452
    • Ilknur Esen Yildiz, MD, Assoc. Prof. · Principal investigator
  • Samsun Ondokuz Mayıs University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Samsun, Turkey (Türkiye)
    Recruiting
    • Ozgur Gunal, MD, Prof. · Contactozgurgop@yahoo.com · +905052543167
    • Ozgur Gunal, MD, Prof. · Principal investigator
  • Şanlıurfa Harran University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Sanliurfa, Turkey (Türkiye)
    Recruiting
    • Tuba Damar Cakirca, MD, Prof. · Contactdr.tubadamar@gmail.com · +905444495379
    • Tuba Damar Cakirca, MD, Prof. · Principal investigator
  • Sivas Cumhuriyet University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Sivas, Turkey (Türkiye)
    Recruiting
    • Seyit Ali Buyuktuna, MD, Prof. · Contactalibuyuktuna@gmail.com · +905053869882
    • Seyit Ali Buyuktuna, MD, Prof. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data collected during the trial will be made available upon reasonable request to qualified researchers for academic purposes following the publication of the primary study results.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication and then.

Access criteria: Data will be shared with qualified academic researchers who provide a methodologically sound proposal. To gain access, data requestors must sign a data use agreement (DUA) and provide proof of institutional review board (IRB) or ethics committee approval for their secondary analysis. The requested data must be used solely for the purposes of the approved research proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Aug 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2026
First posted
Apr 14, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Aug 30, 2026
CompletionEst.
Dec 31, 2029
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07529171
Lead sponsor
Yaşar Bayındır, MD
Collaborators
SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY
Responsible party
Yaşar Bayındır, MD (Chief Physican, Guven Health Group) — Sponsor-investigator
First posted
Apr 14, 2026
Start date
Mar 9, 2026
Primary completion
Aug 30, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Aug 4, 2026

Study contacts

Cigdem Mermutluoglu, MD, Assoc. Prof.
Contact
cigdemmermut@gmail.com
+905052252700
Mustafa Kemal Celen, MD, Prof.
Contact
yasarb44@hotmail.com
+905336207022
Yasar Bayındır, MD, Prof.
study director · Guven Hospital
cigdem Mermutluoglu
principal investigator · Dicle University, Medical Faculty

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion